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Abstract
The incidence of pancreatic cancer has been increasing while its 5-year survival rate has not changed in decades. In
the era of personalized medicine, immunotherapy has emerged as a promising treatment modality in a variety of
malignancies, including pancreatic cancer. This review will discuss the unique pancreatic tumor microenvironment,
including the cells and receptors that transform the pancreas from its normal architecture into a complex mix of
suppressor immune cells and dense extracellular matrix that allows for the unrestricted growth of cancer cells. Next,
we will highlight the recently completed immunotherapy clinical trials in pancreatic cancer. Finally, we will explore
the on-going immunotherapy clinical trials and future directions of this engaging and changing field.
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Background
Despite intensive research efforts to better understand
its tumor microenvironment, the prognosis of pancreatic
cancer remains dismal [1, 2]. The Pancreatic Cancer
Action Network estimates that deaths from pancreatic
cancer will be second only to lung cancer by 2020 [3].
Accordingly, novel treatment strategies for pancreatic
cancer are desperately needed.
Immunotherapy is one of these novel strategies that
has been under investigation in a variety of cancers. This
review will focus on pancreatic cancer from an immune
perspective, describing its immune microenvironment
and the completed and ongoing clinical trials in this area.
Review
Pancreatic cancer from an immune perspective
Pancreatic cancer is unique from an immunological per-
spective. First, intratumoral effector T-cells are rare, in
contrast to many other solid tumors for which infiltra-
tion of effector T-cells is often prominent [4, 5]. Second,
the RAS oncogene drives an inflammatory program that
establishes immune privilege in the pancreatic tumor
microenvironment (PTME) [6]. Third, pancreatic cancer
is associated with a massive infiltration of immunosup-
pressive leukocytes into the tumor microenvironment
[4, 5]. Fourth, the development of pancreatic cancer is
associated with a strong desmoplastic reaction that
consists of multiple cell types, molecular factors, and
extracellular matrix [7]. This dense desmoplastic stromal
reaction is one of the hallmarks of pancreatic cancer and
plays a vital role in promoting angiogenesis while evading
from immune cells [4, 8, 9]. Studies have uncovered a rich
communication between stellate cells (fibroblasts) and
cancer cells [4, 8, 9]. The abundance of PDGF (platelet
derived growth factor), fibronectin, proteoglycans and
hyaluronic acid distorts the normal pancreatic architec-
ture and transforms it into a complex, abnormal configur-
ation of seemingly impenetrable walls [7]. Accordingly,
this extensive stroma is not only a passive barrier for the
immune system but rather interacts with cancer cells and
participates in its progression and invasion [7].
It is useful to examine the immune cells and receptors
in pancreatic cancer based on their role in the develop-
ment of an immune response and their correlation with
prognosis. There are two immunological processes that
determine the immune response against cancer cells: the
effector process and the suppressor process. These cell
types are summarized in Table 1 and Fig. 1.
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Table 1 Cellular Microenvironment of Pancreatic Cancer
Cell Role in pancreatic cancer Relationship to outcome Reference
NK deactivated ↑tumor stage and ↓survival [11–13]
CD8+ T-Cell deactivated ↑tumor stage and ↓survival [5, 8, 13]
CD4+ Th1-Cell ↓ ↑tumor stage and ↓survival [12–14]
TAM (M1) ↓ ↑tumor stage [4, 12–14]
DC deactivated ↑survival [8, 13, 17, 18]
MDSC ↑ ↓survival [5, 12, 16, 24]
Mast Cell ↑ ↑metastases [9, 13]
T-regs ↑ ↓survival [4, 5, 12, 22, 23]
TAM (M2) ↑ ↑stage and ↓survival [4, 12–14]
Fibroblast ↑ ↑stage and ↓survival [12, 13, 25, 27]
CD4 + Th2 Cell ↑ ↑stage and ↓ survival [5, 9, 12–14, 16, 25]
↑ increase, ↓ decrease, DC dendritic cell, MDSC myeloid derived suppressor cell, NK natural killer cell, TAM tumor associated macrophage
Fig. 1 Pancreatic Cancer with Targeted Immunotherapy. DC (dendritic cell), GM-CSF (granulocyte macrophage colony stimulating factor), PD-1
(programmed cell death-1), PDL-1 (programmed cell death ligand-1), CTLA-4 (Cytotoxic T-lymphocyte associated protein-4), HSP (heat shock protein),
TCR (T-cell receptor), MHC (major histocompatibility complex), vEGF-R (vascular epithelial growth factor-receptor), IDO (Indoleamine 2,3-dioxygenase),
TGF (tumor growth factor), IL (interleukin), CD (cell differentiation), V (vaccine)
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Effector immune cells
Natural killer cells (NK) An increased number of NK
cells have been shown to be associated with a better
prognosis in a small set of 13 patients with pancreatic
cancer [10], presumably due to their role in recognition
and elimination of cancer cells. However, NK cells are
typically found in a limited number in pancreatic cancer
and often in a deactivated form due to the lack of
NKG2D, a cell surface receptor found to be upregulated
in activated NK cells [11–13].
CD8 Cytotoxic and CD4 helper T-cells or tumor
infiltrating lymphocytes (TILs) The presence of TILs in
pancreatic cancer has been well described and it may rep-
resent the most important element in PTME [8, 9, 14, 5].
Among these TILs, the memory (CD45RO) CD8 T-cells
are thought to be the major anti-tumor effector cells and
their density in resected pancreatic tumors was found to
correlate with survival [8, 9]. On the other hand, the role
of CD4 T-cells is more complex. The Th1, the effector
form, activates antigen presenting cells (APC) such as
dendritic cells (DCs) while the ineffective form (Th2) plays
a major role in tumor tolerance [13, 5]. Although the pres-
ence of both CD8 and CD4 T-cells correlates with a better
prognosis [4, 8, 15], they are found in small numbers in
the PTME, possibly due to effect of stroma and sup-
pressor immune cells [15]. In addition, the number of
CD8 effector T-cells decreases during the malignant
transformation of pre-cancer cells [5, 8]. Studies have
shown that Th1 cells are found in disproportionately
lower concentrations among pancreatic cancer cells
than Th2, suggesting an ineffective immune response
against tumor cells [5, 16].
Dendritic cells (DCs) The presence of DCs in the
PTIM is essential in order to generate an anti-tumor im-
mune response and, similar to TILs, is associated with a
better prognosis in pancreatic cancer [8, 17, 18]. How-
ever, DCs are present in low numbers in the PTME and
often in an immature form [8, 17, 18], thus likely limiting
their ability to present foreign antigens to T-cells.
Co-stimulatory receptors and ligands
CD40 Is a co-stimulatory molecule that is expressed on
T-cells and binds to its ligand (CD40L) on APCs, leading
to the activation of lymphocytes [13]. In a retrospective
analysis of patients with pancreatic cancer, Unek et al.,
showed that the expression of CD40 in pancreatic cancer
tissue samples correlates with a trend towards improved
progression-free survival (PFS) and overall survival (OS)
[19]. Accordingly, CD40 represents a promising target in
pancreatic cancer as described below.
OX-40 (tumor necrosis factor receptor superfamily
member 4) Is a member of the TNF receptor family
found on T- cells and acts as a secondary co-stimulatory
molecule as it requires other co-stimulatory molecules
to be expressed first prior to its activation. The expres-
sion of OX-40 is found in high concentrations on acti-
vated T-cells. In pancreatic cancer increased levels of
OX-40 was reported to correlate with better survival but
this data needs to be validated on a larger scale [10].
4-1BB (tumor necrosis factor receptor superfamily
member 9) Is also a member of the TNF receptor family
and found on T-cells and NK cells. Upon interaction
with its ligand 4-1BBL, it promotes T cell activation, par-
ticularly CD8 lymphocyte. 4-1BB also acts as a second-
ary co-stimulatory molecule, similar to OX-40 [20, 21].
However, there is currently no data available regarding
the role of 4-1BB in the PTIM.
Suppressor immune cells
Tumor associated macrophages (TAMs) These cells
express the program cell death ligand (PD-L1) which is
involved in immune suppression and T-cell apoptosis as
described below. In PTIM, the presence of TAMs and it
is association with poor outcomes and more frequent
metastases has been well described [4, 13].
T-regulatory cells (CD4 + CD25 + FoxP3+) (T-regs) T-
regs are other subsets of TILs known for their immuno-
suppressive activity through the release of cytokines
including TGF-β and IL-10. Based on few retrospective
analyses, pancreatic tumors with low numbers of T-
regs were found to have a significantly better survival
compared to tumors with high numbers [4, 22, 23].
Myeloid derived suppressor Cell (MDSCs) In pancre-
atic cancer, these cells were found in pre-malignant
growths and increased in concentration as cancer cells
grow suggesting a direct role in immune suppression
and unrestricted cancer cell growth [5, 12, 16, 24]. Inter-
estingly, high concentration of MDSCs in the peripheral
blood was associated with poor outcomes in patients
with pancreatic cancer [16]. Whether this correlation ex-
ists in the PTIM remains to be determined.
Fibroblasts/pancreatic stellate cell Fibroblasts respond
to a variety of molecules including CXCL12 (C-X-C
motif chemokine 12) and produce VEGF (vascular endo-
thelial growth factor) to stimulate angiogenesis in re-
sponse to hypoxia or inflammation [7, 12, 13, 25]. In
pancreatic cancer, the production of VEGF by fibroblasts
is associated with cancer growth and worse prognosis
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[26, 27]. Therefore, the role of fibroblasts in the PTME
is currently under intense investigation.
Mast cells The role of mast cells in cancer has not been
well-defined [9, 28, 29]. In pancreatic cancer, it has been
suggested that low concentration of mast cells in the
PTME correlates with increased survival [28] while in-
creased concentration is associated with increased lymph
node metastases based on retrospective analyses in small
subsets of patients [29].
Co-Inhibitory Receptors and Ligands
Program-death (PD-1) Is an inhibitory receptor that
belongs to the B7-receptor family and interacts with its
ligand PD-L1 (B7-H1) to down regulate signals by T-
cells, leading to the induction of apoptosis in activated
T-cells [13]. PD-1 is expressed on progenitor T cells, ac-
tivated T- and B-lymphocytes, NK cells, and myeloid
cells [13]. Patients with pancreatic cancer with PD-L1
positive tumors have a significantly worse prognosis than
patients with PD-L1 negative tumors [27]. The PD-1/
PD-L1 pathway is currently one of the most targeted
pathways in cancer.
Cytotoxic T-lymphocyte associated protein-4 (CTLA-4)
Is a co-inhibitory molecule found on T- lymphocytes
that deactivates these cells to induce apoptosis in re-
sponse to interaction with APCs. This negative feedback
loop is a key to normal immune function to prevent
over-stimulation of T-cells and damage to healthy cells
but is stimulated inappropriately in pancreatic cancer to
create a microenvironment that promotes cancer growth
rather than its recognition. CTLA-4 is overexpressed in
pancreatic cancer cells and its overexpression was found
to correlate negatively with survival in patients who
underwent surgical resection [30].
CXCL12 (C-X-C motif chemokine ligand 12) Is a che-
mokine that is found in high concentration in pancreatic
cancer and is involved in fibroblast migration and prolif-
eration. The increased concentration of CXCL12 in the
cancer microenvironment creates a network of dense
stroma restricting immune cells migration and recognition
of cancer antigens. Feig et al., showed that the inhibition
of this chemokine resulted in increased T-cell infiltration
into pancreatic cancer in murine models [27].
T-cell immunoglobulin and mucin-domain containing
molecule 3 (TIM-3) Is a transmembrane protein that is
involved in the regulation of Th1 lymphocytes. The
interaction between TIM-3 and CD4 Th1 cells has been
studied in pancreatic cancer patients and found to cor-
relate with tumor vascular invasion [31]. However, the
role of TIM-3 needs to be further characterized in
pancreatic cancer and other malignancies.
Soluble lymphocyte activation gene-3 (LAG-3) Is an
important T-cell regulator that interacts with MHC class
II molecules expressed on APCs. This interaction pro-
motes activation and maturation of DCs but negatively
regulates effector T-cells. LAG-3 has been shown to be
necessary for T-regulatory cell activity and represents a
novel target for therapy in pancreatic cancer [32].
Indoleamine 2,3-dioxygenase (IDO) Is an enzyme in-
volved in cleaving tryptophan into kynurenine. Trypto-
phan is required for T-cell activation and kynurenine
leads to T-regs differentiation and chemotaxis [33]. In-
creased levels of IDO, as seen in pancreatic cancer,
creates a microenvironment devoid of effector T-cells
but rich in immunosuppressive T-regs [34]. IDO inhibitors
are currently under investigation in pancreatic cancer and
other malignancies (NCT02048709 and NCT02077881).
Galectins (Gal-1, Gal-3 and Gal-9) Are immune
modulating glycoproteins that are overexpressed in pan-
creatic cancer cells and thought to be involved in T-cell
homeostasis. These glycoproteins have been shown to
promote immune suppression in pancreatic cancer by
promoting Th2 and T-reg transformation, restricting DC
maturation and stimulating stellate cells [35, 36]. Their
association with survival in pancreatic cancer has been
conflicting, with several studies showing increased con-
centration associated with decreased survival [37, 38],
while others showed an association with improved out-
comes [39].
B7-H3 Is a member of the B7 ligand family that can be
induced in activated dendritic cells, monocytes, and T
cells leading to decrease Th1 type response and cytokine
production. B7-H3 expression was found to correlate
with lymph node metastases and advanced pathologic
stage in patients with pancreatic cancer [40]. The inhib-
ition of B7-H3 increased CD8+ TILs and inhibited
tumor growth in mice [40].
Pancreatic cancer vaccines
Cancer vaccines aim to stimulate the immune system
against tumor cells by generating humoral and/or cellu-
lar immune responses. Many forms of cancer vaccines
exist but generally they can be divided into synthetic and
cellular-based vaccines.
Synthetic vaccines (summarized in Table 2)
Synthetic vaccines are typically made from whole pro-
tein or peptides that match a pre-determined antigen to
induce a T- cell response. Despite multiple large trials
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Table 2 Completed immunotherapy clinical trials
Treatment type Target N Additional therapy Cancer stage Immunologic response Clinical outcome Ref
Peptide vaccines CEA 23 None Resected or
Metastatic
↑ IFN-γ T cell response
by ELISPOT with increasing
vaccine dose
37 % survival at 32 months [77]
CEA +
MUC1
20 None Metastatic NR mOS of 7.3 ms [78]
Gastrin 17 154 None Metastatic 74 % + ELISA ↑OS by 54 % vs placebo (p = 0.03) [51]




Gastrin 17 30 None Metastatic 67 % + ELISA ↑OS (4 to 7.2 ms if + IR (p < 0.01) [52]
GVAX +
Mesothelin
90 Cyclophosphamide Metastatic NR ↑OS (4 to 6.2 ms) [63]
Hedgehog 59 Gemcitabine Metastatic NR mOS 10 ms [79]
KRAS 23 None Resected 85 % + DTH 10 year OS of 20 % [56]
KRAS 48 GM-CSF Resected(10) and
Metastatic (38)
58 % + DTH ↑OS (2 to 5.4 ms if + IR
(p = 0.0002)
[54]
KRAS 24 GM-CSF Resected 11 % + DTH mOS 20.3 ms [55]
KRAS 39 Gemcitabine Resected 47 % + ELISpot ↑OS by 21.7 wks if + IR (p < 0.01) [57]
MUC1 16 SB-AS adjuvant Resected 31 % + DHT No benefit [42]
MUC1 6 Incomplete
Freund's
Metastatic 17 % + ELISA No benefit [41]
Telomerase 1062 Gemcitabine Metastatic NR No benefit [47]
Telomerase 520 Gemcitabine Metastatic NR No benefit [48]
Telomerase 48 GM-CSF Metastatic 63 % + DHT mOS of 4.3 ms if + IR
(p < 0.01)
[50]
Telomerase 178 Gemcitabine Metastatic NR No benefit [49]
Trop-2 7 None Metastatic NR No benefit [80]
VEGF 607 Erlotinib +
Gemcitabine
Metastatic NR No benefit [44]
VEGF 535 Gemcitabine Unresectable NR No benefit alone [46]




32 Gemcitabine Unresectable 58 % + DTH ↑mOS by 7 ms if DHT + (p < 0.01) [81]
Autologous: DC MUC-1 49 Gemcitabine Metastatic ↓65 % T-regs 2 CR, 5 PR ,10 SD [59]
MUC1 17 None Resected and
Unresectable
NR mOS of 9 ms [82]
MUC-1 20 none Metastatic Correlation between
CD38+ cells and OS
1 pt had remission of lung mets,
5 had stable disease. mOS 9.8 mos
[58]
MUC-1 10 None Resected No difference 30 % OS 4 years [83]






10 Gemcitabine Metastatic 57 % + DTH ↑OS if + DTH [85]
Allogeneic GM-CSF 60 5-FU Resected ↑ mesothelin + ELISPOT ↑OS (53 % to 76 % if + IR) [61]
GM-CSF 14 Adjuvant CRT Resected 21 % + DTH DFS of 25 ms if + R [60]
GM-CSF 30 Cyclophosphamide Metastatic ↑Mesothelin ELISPOT No benefit [62]
Adoptive cell
transfer
Mesothelin 6 None Metastatic NR 33 % with stable disease [65]
MUC1 28 None Resected (20)
and Unresectable (8)
↑10 % effector T-cells ,
↓5.7 % Tregs
mOS 5 ms in unresectable,
19 % 3 year OS in resectable
[64]
MUC1 20 None Unresected ↑CD8+ T-cells mOS 9.8 ms,1 year OS 20 % [58]
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targeting MUC1 [41–43], VEGF [44–46], telomerase
[47–50] and gastrin-17 [51–53], none have shown a
meaningful survival benefit. These trials, however, were
able to show significant immune responses to the tar-
geted antigens. Some trials using mutated RAS peptide
vaccine alone [54–56] or in combination with gemcita-
bine [57] have shown clinical benefit. Importantly, this
benefit was mainly seen in patients who demonstrated
positive immune responses [54, 56, 57].
Cellular-based vaccines (summarized in Table 2)
Cellular-based vaccines use cancer cells (either whole
cells or cell lysates) as the source of the antigens, allow-
ing the immune system to utilize multiple antigens ra-
ther than a single epitope. Overall the results of these
trials are encouraging; however, each included a small
number of patients making it difficult for meaningful in-
terpretation. Cellular based vaccines can be divided into
autologous or allogeneic vaccines based on the source of
the cells.
Autologous vaccines In this process, the patient’s own
dendritic cells are isolated and pulsed with a specific
antigen before being re-infused back to the patient. Mul-
tiple studies have used this vaccination approach target-
ing variety of antigens. MUC1 is one of the most
targeted antigens given its overexpression in pancreatic
cancer and its association with tumor invasion and me-
tastasis. The clinical outcome of this vaccination method
was not impressive; however, an interesting correlation
with immune biomarkers was identified such as in-
creased CD38 (a marker for activated lymphocytes) [58]
and decreased T-regs [59].
Allogeneic vaccine In this method of vaccination, a
pancreatic cancer cell line is stimulated, usually with
GM-CSF, in order to elicit an immune response when
administered to patients with pancreatic cancer. A group
at John Hopkins used this form of cancer vaccine
(GVAX) in combination with 5-FU or chemoradiation in
the adjuvant setting and showed an increase in PFS and
OS in patients who developed an immune response
against mesothelin [60, 61]. The same group also investi-
gated GVAX in the metastatic setting in combination
with low dose cyclophosphamide, to deplete T-regs,
demonstrating an increase in mesothelin specific T-cell
response with no survival benefit [62]. More recently,
GVAX was combined with a Listeria vaccine that ex-
presses mesothelin in 90 patients with metastatic dis-
ease. The combination of these 2 vaccines showed an
improved OS compared to the allogeneic vaccine alone
(6.1 vs 3.9 months, p = 0.01). Interestingly, patients who
derived the most benefit of this combination were pa-
tients who received over 3 doses of the vaccine (9.7 vs
4.6 months, p = 0.01) and patients who received at least
2 previous chemotherapy regimens (5.1 vs 3.7 months,
p = 0.001) [63]. This combination has currently a break-
through designation by FDA while being investigated
in patients with metastatic disease in a large ongoing
clinical trial.
Adoptive T- cell transfer (summarized in Table 2)
In this approach the patient’s T-cells are expanded and
activated ex vivo then re-infused back to the patient.
Based on the source and the method used for T-cell
activation, adoptive T- cell transfer could be classified
into: Tumor infiltrating lymphocytes (TILs), engi-
neered T- cells that express a specific cancer T-cell re-
ceptor (TCR), and T- cells that express a chimeric
antigen receptor (CAR). This methodology of im-
munotherapy had gained a lot of attention recently
due to promising clinical outcomes in hematological
malignancies. However, the efficacy of adoptive T- cell
transfer remains to be determined in solid tumors in-
cluding pancreatic cancer. Kawaoka et al., investigated
MUC1-specific cytotoxic T lymphocytes (CTLs) in 28
patients and showed 19 % 3-year survival in patients
with resectable disease along with increased effector
lymphocytes and decreased T-regs [64]. More recently,
the University of Pennsylvania group presented their
Table 2 Completed immunotherapy clinical trials (Continued)
Immune checkpoint
inhibitor
CD40 21 Gemcitabine Unresected (7) and
Metastatic (20)
N/A ↑mOS by 1.7 ms vs gemcitabine
alone, 1 patient had complete
resolution of hepatic metasteses
[68]
CTLA-4 30 GVAX Unresectable or
metastatic
N/A ↑1 year OS by 20 % compared
to GVAX alone
[75]
CTLA-4 27 none Unresected (7) and
Metastatic (20)
N/A 1 patient delayed regression
of hepatic metasteses
[70]
PD-L1 14 none Metastatic N/A No benefit [69]
↑ increase, ↓ decrease, CR complete response, CRT chemoradiation, CTLA-4 Cytotoxic T-lymphocyte associated protein-4, DC dendritic cell, DTH delayed typed
hypersensitivity, GM-CSF granulocyte macrophage colony stimulating factor, MDSC myeloid derived suppressor cell, mOS median overall survival, Ms months, N/A
not applicable, NK natural killer cell, NR not reported, OS overall survival, PD-L1, programmed cell death ligand-1, PR partial response, R response, SD stable disease,
TAM tumor associated macrophages, Wk weeks
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experience using autologous T- cells modified with a
chimeric antigen receptor (CAR) that recognizes
mesothelin in pancreatic cancer patients with refrac-
tory metastatic disease. Of the 6 patients treated 2 had
stable disease with one patient had a decreased PET
avidity of hepatic metastases. Overall, the treatment
was well tolerated [65]. The carcinoembryonic antigen
(CEA) is another attractive target in pancreatic cancer
that is currently been explored in clinical trials
(NCT01723306, NCT00004178 and NCT01212887). New
generations of CAR therapies are under investigation with
a focus on increasing their activities and specificities and
decreasing their toxicities. The CAR T-cells efficacy could
be enhanced by engineering the intracellular domain to
contain co-stimulatory molecules such as 41BB and
OX40 or combining CAR T-cells therapy with immune
modulators such as cyclophosphamide in order to de-
plete T-regulatory cells (NCT02465983) or immune
checkpoint inhibitors such as CTLA-4 and anti-PD1
antibodies.
Immune checkpoint inhibitors and co-stimulatory
agonists (summarized in Table 2)
Immune checkpoint inhibitors represent a paradigm
shift in cancer treatment due to their promising clinical
activities in melanoma and other malignancies [66, 67].
However, a limited number of studies targeting these
immune checkpoints have been completed in pancreatic
cancer. The first study to investigate the co-
stimulatory agonists in pancreatic cancer used CD40
agonist in combination with gemcitabine in 21
patients with locally advanced or metastatic disease.
This study demonstrated promising outcomes with an
improvement of median OS compared to gemcitabine
alone and one patient having a complete resolution of
his liver metastases [68]. In the area of immune
checkpoint inhibitors, both CTLA-4 and PD-L1 inhib-
itors were investigated in patients with locally ad-
vanced or metastatic pancreatic cancer in 2 clinical
trials. The clinical outcomes were disappointing, al-
though, only small number of patients were treated
on both trials [69, 70]. To date, the only immune
checkpoint inhibitor to show activity in pancreatic
cancer is MEDI4736 (anti-PD-L1), which showed a
PR rate of 8 % in a preliminary analysis of this going
trial [71]. While this suggests a response can be
achieved with single immunotherapy, it remains dis-
mal and maybe improved by combination therapy.
This approach is currently being investigated in few
ongoing trials as detailed in Table 3.
Combination therapy
Due to the lack of meaningful clinical benefits of cancer
vaccines, the potential positive immunological effect of
chemotherapy and radiation therapy, and the promising
outcomes of immune checkpoint inhibitors, the focus
has shifted towards combining these modalities. Gemci-
tabine, a standard chemotherapy that is used tradition-
ally to treat pancreatic cancer, has been found to
mediate immunological effects such as tumor associated
antigen cross presentation by dendritic cells and the in-
duction and expansion of cytotoxic T cells responses in
addition to reduce the number of myeloid suppressor
cells [72, 73]. Radiation therapy can also increase the im-
munogenic properties of tumor cells by enhancing MHC
class I expression, thereby increasing their vulnerability to
CTLs. Another frequent effect of DNA damage inflicted
by radiotherapy or chemotherapy is the increase in the ex-
pression of death receptors (in particular Fas/CD95 and
TNF-related apoptosis-inducing ligand [TRAIL] receptors,
enabling lysis of the tumor cells by Fas/CD95 ligand and
TRAIL-positive immune effectors [74]. As detailed in
Table 3, the majority of ongoing trials investigate a com-
bination strategy of the immunotherapy with chemother-
apy, radiation or both. Of interest are multiple trials
targeting mesothelin and/or GVAX with chemoradiation
and multiple immune checkpoint inhibitors combined
with chemotherapy. Our group is currently investigating
the immunological effect of the combination of chemora-
diation and anti-PD-1 as a neoadjuvant treatment in pa-
tients with resectable or borderline resectable pancreatic
cancer compared to neoadjuvant chemoradiation alone
(NCT02305186). This neoadjuvant setting will allow in-
vestigators to study the effect of combination therapy on
the tumor microenvironment. Another promising com-
bination by the Hopkins group combined GVAX with
anti-CTLA-4 and demonstrated a 1-year improvement in
OS by 20 % compared to GVAX and cyclophosphamide
alone [75].
Conclusion
Despite the ongoing efforts outlined in this review, the
prognosis of pancreatic cancer remains dismal. With
the recent progress in cancer immunotherapy, there
are glimmers of hope in new immune targets with
more being identified each year. These advancements
are moving from the bench to the bedside at a rapid
pace, with the hope of translating into improvements
in clinical outcomes. We believe that immunotherapy
represents a promising modality in pancreatic cancer.
However, there still remains much to be learned about
the pancreatic immune microenvironment and its role
in the immune escape of cancer cells. In order to
develop an active strategy to enhance the immune
response against pancreatic cancer that could be trans-
lated to a promising clinical outcome we must focus
our efforts on increasing the density of the intratu-
moral effector T-cells; decreasing or inhibiting the
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Table 3 On-going immunotherapy clinical trials
Treatment type Phase Target N Additional therapy Stage Identifier
Chimeric antibody I,II Ensituximab 116 None Metastatic NCT01040000a
DNA vaccine I VEGFR-2 72 None Metastatic NCT01486329a
Fungal vector
vaccine
II RAS 176 Gemcitabine Resected NCT00300950a
Viral vector
vaccine
I Small Pox Virus 36 None Metastatic NCT00574977a
Allogeneic vaccine I CEA 48 GM-CSF Metastatic NCT00028496a
I Donor Lymphocyte 37 None Metastatic NCT00161187a
I Dendritic cells 12 Poly-ICLC Unresectable NCT01677962
II GM-CSF 60 Cetuximab + Cyclophosphamide Metastatic NCT00305760a
II GVAX 56 None Metastatic NCT00389610
II GVAX 87 Cyclophosphamide Resectable NCT0072744
II GVAX 19 Cyclophosphamide, Radiation,
FOLFIRINOX
Resected NCT01595321
II GVAX +/- Mesothelin 93 Cyclophosphamide Metastatic NCT01417000




II IFN-α + GM-CSF 14 Cyclophosphamide Metastatic NCT00002773a
III Virulizin 400 Gemcitabine +/- 5-FU Metastatic NCT00040092a
Autologous
vaccine
I CEA 24 None Metastatic NCT00004604a
I CEA 14 None Metastatic NCT00027534a
I CEA 24 Denileukin Diftitox Metastatic NCT00128622a
II CEA 48 IL-2 Metastatic NCT01723306
I Dendritic Cells 2 Gemcitabine + Stereotactic
Radiosurgery
Metastatic NCT00547144a
II KLH 35 Radiation Metastatic NCT00868114
Immunotherapy I B7-H3 93 none All NCT01391143
I CD40 10 Gemcitabine + nab-paclitaxel Metastatic NCT02588443
I CD40 10 Gemcitabine resected NCT01456585a
II CTLA-4 82 None Metastatic NCT00112580a
I CTLA-4 37 Gemcitabine Metastatic NCT00556023a
I CTLA-4 28 Gemcitabine Metastatic NCT01473940
II CTLA-4 + GVAX 92 FOLFIRINOX Metastatic NCT01896869
II IDO 98 Gemcitabine + nab-paclitaxel metastatic NCT02077881
I IL-1-Ra 13 FOLFIRINOX Metastatic NCT02021422
I/II PD-1 56 Capecitabine + Radiation Resectable and Borderline
Resectable
NCT02305186
I PD-L1 1038 none All NCT01693562
Peptide vaccine I,II Alpha (1, 3)
galactosyltransferase
7 None Metastatic NCT00255827a
III Alpha (1, 3)
galactosyltransferase
280 FOLFIRINOX Locally Advanced NCT01836432
III Alpha (1,3)
galactosyltransferase
722 Gemcitabine, 5-FU, radiation Resected NCT01072981
I,II CEA 28 None Metastatic NCT00529984a
I CEA +MUC1 18 None Unresectable NCT00669734
I hCG-β 36 None Metastatic NCT00648102a
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immunosuppressive cells and receptors; and under-
standing the role of the stromal reaction and its inter-
action with pancreatic cancer immune microenvironment.
Indeed, the recent encouraging data of patients with
mismatch-repair deficient colorectal cancer responding to
pembrolizumab requires further investigation, particularly
as it may be relevant for a small number of patients with
pancreatic cancer [76]. Improved response rates and
survival benefits may be achieved by using combination
therapies; identifying novel biomarkers in order to select
the group of patients who may drive the most benefit of
cancer immunotherapy; and implementing novel clinical
trials designs that allow for tumor samples collection in
order to understand the mechanism of action and resist-
ance of pancreatic cancer to immunotherapy.
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I/II Hedgehog 122 Gemcitabine Metastatic NCT01130142a
I Hedgehog 21 FOLFIRINOX Unresectable NCT01383538
I MUC1 25 None Resected or Locally Advanced NCT00008099a
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I RAS 7 None Metastatic NCT00006387a
I RAS 33 None Metastatic NCT00019006a
III Telomerase 1110 Capecitabine + Gemcitabine Metastatic NCT00425360a
I TGF-β 168 Gemcitabine Resectable and unresectable NCT01373164
I Trophoblast glycoprotein 44 None Metastatic NCT00056537a
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keyhole limpet hemocyanin, MUCmucin, N number, PD programmed death, PD-L programmed death ligand, Poly-ICLC carboxymethylcellulose, polyinosinic-polycytidylic acid,
and poly-L-lysine double-stranded RNA, TGF Transforming growth factor, VEGF Vascular endothelial growth factor, VEGF-R Vascular endothelial growth factor receptor
aStudy listed as complete but results not published
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